Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics is supported by a rapidly scaling Filspari franchise, with 3Q26 revenue of $200.2M, up 120% year over year and 42% sequentially, while management still guides to more than $3B in peak U.S. sales by 2033. The company’s outlook improves further because FSGS adoption is still early—roughly two-thirds of prescribers have treated only one patient, conversion to paid therapy is nearing IgAN levels, and switching away from Filspari remains low even as new IgAN entrants arrive. Beyond the core launch, a strengthened patent position through October 2037 and pipeline catalysts for pegtibatinase in 2H27 and civorebrutinib by year-end 2026 extend the growth runway, despite a 3Q26 net loss of $52.3M and $471.8M in cash and investments.

Travere Therapeutics is facing a negative fundamental setup because its valuation depends heavily on commercial, clinical, and regulatory execution across Thiola, Filspari, and its development pipeline, leaving little room for disappointment. Even with $471.8M in cash, cash equivalents and marketable securities at the end of 3Q 2026 and $489.2M at the end of 1Q 2026, the company may still need additional capital, and a follow-on stock offering could dilute current investors. Delays or setbacks in commercializing Filspari or pegtibatinase could materially reduce sales potential and undermine confidence in the company’s long-term prospects.